| 摘要 |
<p>Mdm2 binds to p53 in cells in which mdm2 is not overexpressed, i.e. in cells in which mdm2 is expressed at normal or low levels, and that in these cells, this interaction targets the p53 for degradation. This finding means that inhibiting mdm2 production and/or inhibiting the binding of mdm2 to p53 allows levels of p53 to increase by reducing the clearance of p53 by mdm2, and can be used to activate p53 function in cells other than those in which mdm2 is overexpressed. This allows the use of an agent having the property of disrupting the binding of p53 and mdm2 or inhibiting the production of mdm2 in a population of cells, in the preparation of a medicament for activating p53, wherein the population of cells do not overexpress mdm2. Such medicaments are useful in the treatment of conditions such as cancer, viral infections or conditions in which p53 or mdm2 is not functional.</p> |
